MXPA01010393A - Tratamiento de neoplasmas con virus. - Google Patents

Tratamiento de neoplasmas con virus.

Info

Publication number
MXPA01010393A
MXPA01010393A MXPA01010393A MXPA01010393A MXPA01010393A MX PA01010393 A MXPA01010393 A MX PA01010393A MX PA01010393 A MXPA01010393 A MX PA01010393A MX PA01010393 A MXPA01010393 A MX PA01010393A MX PA01010393 A MXPA01010393 A MX PA01010393A
Authority
MX
Mexico
Prior art keywords
viruses
neoplasms
treatment
relates
ifn
Prior art date
Application number
MXPA01010393A
Other languages
English (en)
Inventor
Michael S Roberts
Original Assignee
Pro Virus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Virus Inc filed Critical Pro Virus Inc
Publication of MXPA01010393A publication Critical patent/MXPA01010393A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invencion se relaciona con virus que son capaces de replicarse y mediante esto eliminar celulas neoplasicas con una deficiencia en la respuesta antiviral mediada por interferon, y su uso para tratar enfermedad neoplasica que incluye cancer y tumores grandes. Los virus de ADN y ARN son utiles con respecto a esto. La invencion tambien se relaciona con metodos para la seleccion, el diseno, la purificacion y el uso de estos virus para la terapia contra el cancer.
MXPA01010393A 1999-04-15 2000-04-17 Tratamiento de neoplasmas con virus. MXPA01010393A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29237699A 1999-04-15 1999-04-15
PCT/US2000/010204 WO2000062735A2 (en) 1999-04-15 2000-04-17 Treatment of neoplasms with viruses

Publications (1)

Publication Number Publication Date
MXPA01010393A true MXPA01010393A (es) 2004-04-02

Family

ID=23124408

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01010393A MXPA01010393A (es) 1999-04-15 2000-04-17 Tratamiento de neoplasmas con virus.

Country Status (11)

Country Link
US (1) US8043612B2 (es)
EP (1) EP1390046A4 (es)
JP (1) JP2003530301A (es)
CN (1) CN1477964A (es)
AU (1) AU4246900A (es)
CA (1) CA2370187C (es)
HU (1) HUP0302278A3 (es)
IL (1) IL145899A0 (es)
MX (1) MXPA01010393A (es)
NZ (1) NZ550861A (es)
WO (1) WO2000062735A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1218019B1 (en) * 1999-09-17 2006-03-08 Wellstat Biologics Corporation Oncolytic vesicular stomatitis virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
JP5208343B2 (ja) 2000-06-26 2013-06-12 ウェルスタット バイオロジクス コーポレイション ウイルスを用いる細胞の浄化
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
US6750043B2 (en) * 2001-04-19 2004-06-15 Arizona Board Of Regents Viral vectors having reduced virulence
NZ527687A (en) * 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
CA2352439A1 (en) * 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
JP2006511450A (ja) 2002-06-21 2006-04-06 ウェルスタット バイオロジクス コーポレーション 治療用ウイルスの投与
EP1523333A4 (en) 2002-07-24 2007-01-24 Univ Arizona USE OF VACCINIA VIRUS WITH DELETION OF E3L GENE AS VACCINE VECTOR
AU2012261681B2 (en) * 2002-08-12 2014-10-02 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
KR20120002613A (ko) * 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
AU2004216928B2 (en) 2003-03-07 2007-03-08 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
NZ543058A (en) * 2003-03-24 2008-04-30 Wellstat Biologics Corp Newcastle disease virus administration
CA2520279C (en) 2003-03-27 2012-09-04 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
ATE478137T1 (de) 2003-06-20 2010-09-15 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
US20070036758A1 (en) * 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
WO2005014017A1 (ja) * 2003-08-08 2005-02-17 Yuji Shino 癌治療用医薬組成物
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
RU2458125C2 (ru) 2004-11-05 2012-08-10 Веллстат Байолоджикс Корпорейшн Способ стабилизации вируса ньюкаслской болезни для хранения в водном растворе и способ сохранения его стабильности
BRPI0517834A (pt) 2004-11-12 2008-10-21 Bayer Schering Pharma Ag vìrus da doença de newcastle recombinante
US7303898B2 (en) 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
JP5190958B2 (ja) 2005-07-14 2013-04-24 ウェルスタット バイオロジクス コーポレイション ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int ATTENUATED REOVIRUS
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
WO2007030668A2 (en) 2005-09-07 2007-03-15 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
WO2007143548A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Myxoma virus mutants for cancer treatment
CN105769931B (zh) 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
EP2202297B1 (en) * 2007-07-18 2014-05-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
WO2009143468A1 (en) * 2008-05-22 2009-11-26 Uti Limited Partnership Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
WO2010080570A2 (en) * 2008-12-18 2010-07-15 New York University Tumor therapy with antitumor agents in combination with sindbis virus-based vectors
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
CN107303302A (zh) 2009-09-14 2017-10-31 希拉金股份有限公司 溶瘤牛痘病毒组合癌症疗法
ATE539148T1 (de) 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
ES2492691T3 (es) * 2010-06-10 2014-09-10 Intervet International B.V. Composición antitumoral
CA2818701A1 (en) 2010-11-22 2012-05-31 Nova Southeastern University Modulating oncolytic vsv and upregulating rae1 and nup98 with statins
BR112013017096A2 (pt) 2011-01-04 2020-09-01 Jennerex Inc. composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor
CA2905272A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
JP6857498B2 (ja) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための併用方法
CA2970954C (en) 2015-01-26 2023-10-31 Ottawa Hospital Research Institute Compositions and methods for viral sensitization
CN105754952B (zh) * 2016-02-16 2020-07-10 中国农业科学院兰州兽医研究所 抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
WO2017180344A2 (en) * 2016-04-14 2017-10-19 Trizell Ltd. Viral vector stabilization
US10842835B2 (en) 2016-05-25 2020-11-24 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US10786537B2 (en) 2016-08-18 2020-09-29 Cedars-Sinai Medical Center Method of inducing an oncolytic effect on tumor cells using Zika virus
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
PT3518948T (pt) 2016-10-03 2023-07-17 Ottawa Hospital Res Inst Composições e métodos para melhorar o crescimento, a propagração e a eficácia imunoterapêutica de oncolítica de vírus de rna oncolíticos
BR112018075281A2 (pt) 2017-05-10 2020-02-11 Wellstat Immuno Therapeutics, Llc Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
JPS58116422A (ja) 1981-12-28 1983-07-11 Green Cross Corp:The 抗腫瘍剤
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
NZ224567A (en) 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
WO1989007445A1 (en) 1988-02-11 1989-08-24 Board Of Regents, The University Of Texas System Improved method for treatment of cancer with activated oncolytic leukocytes
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5198336A (en) 1989-05-08 1993-03-30 Wisconsin Alumni Research Foundation Bioassay for chemicals which generate prooxidant states
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
PT713397E (pt) 1992-03-24 2003-04-30 United Cancer Res Inst Vacina que contem virus vivos
IL101410A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE199568T1 (de) 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
US5633274A (en) 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
FR2699082B1 (fr) 1993-02-22 1995-05-05 Pasteur Institut Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.
PT1314431E (pt) * 1993-04-30 2008-10-24 Wellstat Biologics Corp Composições purificadas de vírus da doença de newcastle
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
JPH10505320A (ja) 1994-05-31 1998-05-26 イネックス ファーマシューティカルズ コーポレイション 治療剤のビロゾーム媒介細胞内輸送
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
DE69534791T2 (de) 1994-11-28 2006-08-31 Cell Genesys, Inc., South San Francisco Vektoren zur gewebsspezifischen replikation
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
WO1996016676A1 (en) 1994-11-28 1996-06-06 Genetic Therapy, Inc. Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
JPH11500736A (ja) 1995-02-24 1999-01-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子治療ベクターを投与するための方法及び組成物
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5853716A (en) 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
EP0954591A2 (en) * 1996-05-31 1999-11-10 Baxter International Inc. Mini-adenoviral vector
JPH105342A (ja) * 1996-06-27 1998-01-13 A S A Sangyo Kk 経腹膜投薬用カテーテル及び投薬容器セット
WO1999004026A2 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
WO1999018799A1 (en) * 1997-10-09 1999-04-22 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6177076B1 (en) 1997-12-09 2001-01-23 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
EP1073442A1 (en) 1998-04-30 2001-02-07 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
KR20060080249A (ko) * 1998-06-12 2006-07-07 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
EP1150696B1 (en) 1999-02-05 2006-05-10 Arch Development Corporation Genetically engineered herpes virus for the treatment of tumours
AU2905199A (en) * 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer

Also Published As

Publication number Publication date
CA2370187A1 (en) 2000-10-26
WO2000062735A2 (en) 2000-10-26
JP2003530301A (ja) 2003-10-14
CN1477964A (zh) 2004-02-25
EP1390046A4 (en) 2005-04-20
CA2370187C (en) 2011-08-02
US8043612B2 (en) 2011-10-25
US20090081161A1 (en) 2009-03-26
HUP0302278A2 (hu) 2003-10-28
WO2000062735A3 (en) 2003-11-27
IL145899A0 (en) 2002-07-25
EP1390046A2 (en) 2004-02-25
AU4246900A (en) 2000-11-02
NZ550861A (en) 2009-03-31
HUP0302278A3 (en) 2011-01-28

Similar Documents

Publication Publication Date Title
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
IL135507A0 (en) Treatment of neoplasms with viruses
EP1381280A4 (en) VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS
FI973467A (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
CY2008007I2 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
MXPA03003011A (es) Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
CA2283198A1 (en) Butyrate prodrugs derived from lactic acid
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
IL151926A0 (en) Drug for stimulating leucopoiesis and for treating tumour diseases, protozoal diseases, acariasis and arthropodiasis, and process for producing it
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
AU9183698A (en) A new chemical entity (endipalene) in the treatment of psoriasis
BR0012380A (pt) 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples
WO2004098504A3 (en) Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines and methods of treating tumors
WO2000056351A3 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
ATE309354T1 (de) Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen
RU98123495A (ru) Способ лечения рака путем химического выключения "взбесившейся" (crazy) хромосомы
RU97113660A (ru) Способ лечения детей, больных вторичным панкреатитом

Legal Events

Date Code Title Description
FA Abandonment or withdrawal